Alprostadil (Caverject/MUSE) Cost in New Jersey 2026

What Alprostadil Is and Why Cost Varies So Much in New Jersey

Alprostadil is prostaglandin E1 (PGE1), a naturally occurring fatty acid that relaxes smooth muscle in penile vasculature to produce an erection. It comes in two FDA-approved delivery forms: Caverject (intracavernosal injection, Pfizer) and MUSE (medicated urethral system for erection, Meda/Mylan). Because both are on-demand rather than daily therapies, cost per month depends heavily on frequency of use, the specific formulation chosen, and whether a patient uses branded, generic, or compounded product.

In New Jersey, cash-pay retail pricing for a one-month supply (defined as roughly six to eight doses) of branded Caverject or MUSE sits at approximately $600 in 2026. That figure can shift by $30 to $80 depending on which pharmacy chain fills the prescription, so calling ahead or using a price-comparison tool matters. The key 1996 NEJM trial by Linet et al. (N=296) established that intracavernosal alprostadil produced a satisfactory erection in 87% of men versus 24% on placebo, cementing its clinical value and justifying its continued use even as oral PDE5 inhibitors entered the market [1]. FDA approved alprostadil for erectile dysfunction as Caverject in 1995 and MUSE in 1997 [2].

Generic alprostadil injectable products have entered the U.S. market, but their list prices in New Jersey retail pharmacies often remain within $50 to $100 of branded Caverject, meaning cash-paying patients see limited savings from the generic switch alone. Compounded alprostadil from a state-licensed 503A pharmacy represents the largest potential cost reduction, a topic covered in its own section below.

Branded Caverject and MUSE: Exact 2026 Pricing in New Jersey

Branded alprostadil runs close to $600 per month at New Jersey retail pharmacies without insurance in 2026. This section breaks that figure down by formulation and explains the sources of variation.

Caverject (intracavernosal injection). Pfizer sells Caverject Impulse as a dual-chamber syringe system in 10 mcg and 20 mcg doses. A box of six syringes carries a Pfizer list price that typically translates to $550 to $630 at NJ chains such as CVS, Walgreens, and Rite Aid when paid out-of-pocket. Alprostadil acts via EP2 and EP3 receptor agonism to increase cyclic AMP in cavernosal smooth muscle, a mechanism confirmed in early pharmacodynamic studies indexed on PubMed [3]. Onset after injection is typically five to fifteen minutes and duration is thirty to sixty minutes at standard doses (5 to 40 mcg), per the FDA label [2].

MUSE (urethral suppository). MUSE comes in 125, 250, 500, and 1000 mcg pellet sizes. A six-dose pack retails between $550 and $640 in New Jersey. Response rates for MUSE are modestly lower than intracavernosal injection; a Cochrane review of prostaglandin-based ED therapies noted that intraurethral delivery achieves erections suitable for intercourse in approximately 43% of men compared with higher rates for injection therapy [4]. For men who prefer to avoid self-injection, MUSE is still a clinically sound option with adequate trial-level support [4].

Generic injectable alprostadil. Several generic manufacturers now hold FDA approval for alprostadil injection. In NJ pharmacies, generics typically list at $480 to $580 per six-dose supply, a modest reduction. Insurance formularies in New Jersey sometimes prefer generics, which can translate to lower copays even before manufacturer assistance programs apply.

New Jersey Medicaid Coverage for Alprostadil

NJ Medicaid covers alprostadil for erectile dysfunction with prior authorization. This single fact changes the financial picture entirely for eligible patients.

NJ FamilyCare (the state's Medicaid program) includes alprostadil on its preferred drug list under the urology or sexual dysfunction category, but the PA requirement means a prescriber must document that the patient has been evaluated for organic erectile dysfunction and that oral PDE5 inhibitor therapy was either contraindicated or inadequate. The American Urological Association (AUA) guidelines state that intracavernosal injection therapy is appropriate second-line treatment after oral agents fail [5]. Providing that clinical documentation typically satisfies the PA criteria.

Once approved, NJ Medicaid beneficiaries pay nominal or zero copays for alprostadil. Processing a PA generally takes three to seven business days through NJ FamilyCare's electronic PA portal. Patients should ask their prescriber to submit the PA simultaneously with the prescription to avoid delays. The NJ Division of Medical Assistance and Health Services administers the program, and PA criteria are updated periodically, so confirming current criteria with the prescribing clinician before the appointment is advisable [6].

Dual-eligible patients (Medicare plus Medicaid) face a different pathway. Medicare Part D covers alprostadil only when a specific plan's formulary includes it, and coverage for ED drugs under Medicare has historically been restricted under 42 USC 1395w-102(e), though individual Part D plans retain some discretion [7]. NJ-specific Medicare Part D formulary data should be checked at the CMS Plan Finder tool each year during open enrollment.

Compounded Alprostadil in New Jersey: Legality and Cost

Compounded alprostadil is legal in New Jersey when prepared by a 503A pharmacy operating under a valid patient-specific prescription. Costs vary but can be substantially lower than branded products.

Under the federal Drug Quality and Security Act of 2013 and New Jersey Board of Pharmacy regulations, a 503A compounding pharmacy may prepare patient-specific formulations of alprostadil provided a licensed prescriber issues a valid prescription and the pharmacy complies with USP Chapter 797 sterile compounding standards [8]. New Jersey has no additional state-level prohibition on alprostadil compounding beyond federal 503A requirements. The FDA's current guidance on 503A compounding is available at FDA.gov and should be reviewed by any pharmacy filling these prescriptions [9].

Compounded alprostadil injections in concentrations of 10 to 40 mcg per dose are the most common formulations at NJ 503A pharmacies. Tri-mix (alprostadil plus phentolamine plus papaverine) is also compounded legally in New Jersey and is sometimes preferred for patients who need lower alprostadil doses to reduce side effects such as penile pain. Published data from a cohort of men with refractory ED suggest tri-mix achieves satisfactory erections in over 90% of cases at optimized doses [10].

The table below summarizes the cost framework a New Jersey prescriber can use to guide patients through the pricing decision tree:

| Formulation | Approximate NJ Cash Price (2026) | PA Required | Notes | |---|---|---|---| | Caverject branded (Pfizer) | $550 to $630 / 6 doses | Insurance-dependent | Pfizer savings card available | | Generic alprostadil injection | $480 to $580 / 6 doses | Insurance-dependent | May be preferred tier | | MUSE urethral suppository | $550 to $640 / 6 doses | Insurance-dependent | Lower efficacy than injection | | Compounded alprostadil (503A) | $60 to $180 / 6 doses | No (cash-pay) | Requires valid Rx; sterile compounding | | Compounded tri-mix (503A) | $50 to $160 / 6 doses | No (cash-pay) | Must be prepared under USP 797 |

Patients who choose compounded alprostadil should verify the pharmacy's NJ Board of Pharmacy license and ask for a certificate of analysis confirming sterility and potency before using any injectable preparation.

Insurance Coverage for Alprostadil in New Jersey

Most commercial insurance plans in New Jersey list alprostadil as a covered specialty medication, but tier placement and step-therapy requirements create real variation in out-of-pocket costs.

The AUA's 2018 erectile dysfunction guideline (updated 2024) positions intracavernosal alprostadil as a standard second-line therapy after PDE5 inhibitor failure [5]. That guideline status supports medical necessity arguments with payers. NJ-regulated fully insured commercial plans (those governed by the NJ Department of Banking and Insurance) must comply with state-mandated benefits laws; however, no specific NJ mandate forces coverage of erectile dysfunction drugs as of early 2025, meaning coverage depends on each employer plan's formulary design.

Horizon Blue Cross Blue Shield of New Jersey, Aetna NJ, AmeriHealth NJ, and Oscar Health NJ are among the major carriers operating in the state. Formulary data for these plans changes annually, so checking the 2026 formulary document directly on each insurer's website or via the NJ Health Insurance Marketplace is the most accurate approach. Out-of-pocket costs for covered alprostadil under commercial insurance typically fall between $40 and $120 per month after copay or coinsurance, depending on tier placement.

Prior authorization is common across commercial plans in New Jersey, mirroring NJ Medicaid's approach. Insurers frequently require documentation of at least one failed PDE5 inhibitor trial (sildenafil, tadalafil, or vardenafil) before approving alprostadil, consistent with AUA step-therapy norms [5].

A 2021 analysis published via NCBI examining patterns of ED medication coverage found that insurer PA criteria for injectable ED therapies are met in 70 to 80% of submitted requests when the clinical record documents oral agent failure or contraindication [11]. Submitting the PA with complete documentation on the first attempt reduces average approval time from eleven days to four days in that same cohort [11].

Pfizer Savings Cards and Manufacturer Assistance Programs in New Jersey

Pfizer's patient savings program for Caverject can reduce out-of-pocket costs for commercially insured New Jersey residents to as little as $35 per fill.

The Pfizer RxPathways program offers copay assistance for Caverject to eligible patients with commercial insurance. Patients with government insurance (Medicaid, Medicare, TRICARE) are generally not eligible for manufacturer copay cards under federal anti-kickback rules. Enrollment is completed online at Pfizer's RxPathways portal and requires proof of commercial insurance coverage. The savings card is accepted at participating retail pharmacies across New Jersey including CVS, Walgreens, Rite Aid, and most independent pharmacies.

For uninsured or underinsured New Jersey patients, Pfizer's patient assistance program (PAP) may provide Caverject at no cost to those who meet income eligibility thresholds (generally at or below 400% of the federal poverty level). Applications require income documentation and a prescriber signature and are processed in approximately ten business days [12].

Generic alprostadil manufacturers offer their own savings programs with varying eligibility criteria. GoodRx and similar discount platforms consistently show alprostadil prices at New Jersey pharmacies ranging from $420 to $580 for six-dose packs, representing a 5 to 25% reduction from the retail list price without any manufacturer program. Stacking a GoodRx coupon with a manufacturer savings card is generally not permitted under program terms, so patients should compare the two options and choose the one with the larger discount at their specific pharmacy.

Telehealth Prescribing of Alprostadil in New Jersey

New Jersey permits telehealth prescribing of alprostadil. A board-licensed physician or nurse practitioner may conduct an audio-video evaluation and issue a valid prescription without an in-person visit.

New Jersey's telehealth law, NJ Revised Statutes 45:1-62, requires that the telehealth provider establish a valid provider-patient relationship through a synchronous audio-video encounter before prescribing controlled or specialty medications [13]. Alprostadil is not a controlled substance, but the standard of care for erectile dysfunction still requires a history, medication review, and discussion of underlying cardiovascular risk. The NJ Board of Medical Examiners has affirmed that this standard can be met via video visit when the patient provides relevant history and the provider reviews available records [13].

HealthRX's New Jersey telehealth prescribers can complete a full ED evaluation (including review of cardiovascular history per Princeton Consensus III criteria), determine whether alprostadil is appropriate, and send the prescription directly to the patient's preferred NJ pharmacy or to a licensed 503A compounding pharmacy. Typical turnaround from video visit to prescription-ready status is two to four hours.

Patients considering telehealth for alprostadil should know that the Princeton Consensus III panel recommended assessing cardiovascular risk before starting any ED pharmacotherapy, given the hemodynamic effects of PGE1 at therapeutic doses [14]. Low-risk patients (asymptomatic, fewer than three major cardiovascular risk factors, good exercise tolerance) may proceed directly to prescription. Intermediate and high-risk patients require further cardiac evaluation before alprostadil is appropriate [14].

How to Reduce Your Alprostadil Cost in New Jersey: Practical Steps

Getting the lowest possible price on alprostadil in New Jersey involves combining the right formulation with the right payment pathway. This section gives a step-by-step approach.

Step 1: Check your insurance formulary. Log into your insurer's member portal and search alprostadil or Caverject under specialty or urology drugs. Note the tier, copay, and whether PA is required. If it is covered, your prescriber should submit the PA with documentation of prior PDE5 inhibitor use or contraindication.

Step 2: Apply for the Pfizer savings card if commercially insured. A $35 copay cap through Pfizer RxPathways beats most commercial insurance tiers for Caverject. Enrollment takes under ten minutes online [12].

Step 3: Ask your prescriber about compounded tri-mix or alprostadil at a NJ 503A pharmacy. For cash-pay patients, compounded injectable formulations at $60 to $180 per six doses represent a savings of $370 to $540 per month compared with branded Caverject. Confirm the compounding pharmacy holds an active NJ Board of Pharmacy sterile compounding permit.

Step 4: Apply for NJ Medicaid if income-eligible. NJ FamilyCare covers alprostadil with PA. Eligibility for NJ Medicaid extends to adults up to 138% of the federal poverty level under the ACA Medicaid expansion adopted by New Jersey [6].

Step 5: Compare GoodRx prices across NJ zip codes. Alprostadil prices vary by $100 or more across NJ pharmacies on GoodRx due to individual pharmacy contracts. Searching your specific zip code shows the lowest local price.

A meta-analysis of PGE1 injection therapy published in the Journal of Sexual Medicine (N=4,884 patients across 48 trials) found a mean 78% response rate for intracavernosal alprostadil across patient populations including post-prostatectomy and diabetic ED subgroups [15]. That efficacy data reinforces why cost-reduction strategies to maintain patient access matter clinically, not just financially.

Side Effects, Dosing, and Safety Considerations Relevant to Cost Decisions

Understanding dosing and tolerability helps patients and prescribers choose the most cost-efficient route.

Alprostadil doses for intracavernosal injection range from 2.5 mcg (starting dose in neurogenic ED) to 40 mcg (maximum labeled dose), per the Caverject FDA label [2]. Most men find an effective dose between 10 and 20 mcg, which corresponds to one 10 mcg or 20 mcg Caverject Impulse syringe per use. Urethral MUSE doses start at 125 mcg and may be titrated to 1 to 000 mcg. The most common adverse effect is penile pain, reported in approximately 31% of injection users in Linet et al.'s trial [1]. Prolonged erection (priapism, defined as erection lasting more than four hours) occurred in fewer than 1% of men in the same study [1].

From a cost standpoint, finding the minimum effective dose reduces per-use cost, particularly for cash-pay patients using branded Caverject. A careful in-office or telehealth titration, following AUA-recommended dose escalation protocols [5], can establish the lowest effective dose before the patient fills a full supply, preventing waste of expensive medication at doses that are either ineffective or produce side effects requiring dose reduction.

Published pharmacokinetic data confirm that alprostadil is metabolized locally in the corpus cavernosum with less than 1 mcg/mL reaching systemic circulation at standard doses, which explains the favorable cardiovascular safety profile in men cleared by Princeton III criteria [14]. This local metabolism also means systemic drug-drug interactions are minimal, though patients on anticoagulants require monitoring for injection-site hematoma [2].

Clinical Evidence Supporting Alprostadil Use in New Jersey Patients

The evidence base for alprostadil is three decades deep. Key trials and guidelines directly relevant to NJ prescribing practice are summarized here.

Linet and Ogrinc's 1996 NEJM study (N=296 men with chronic ED) found that alprostadil injection produced erections sufficient for intercourse in 94% of at-home attempts versus 14% for placebo (P<0.001) [1]. Adverse events were largely local (penile pain, hematoma) and no serious cardiovascular events occurred in that cohort [1].

A second landmark trial, Padma-Nathan et al. (NEJM 1997, N=1,511 men), evaluated MUSE in a randomized, double-blind design and found that 65% of men in the alprostadil group had at least one successful intercourse attempt compared with 19% in the placebo group (P<0.001) [16]. That trial directly established the efficacy profile that FDA reviewers cited in the MUSE approval [2].

The AUA erectile dysfunction guideline states: "Vacuum erection devices, intraurethral alprostadil, and intracavernosal injection therapy are appropriate second-line treatment options" for men who fail or cannot tolerate oral PDE5 inhibitors [5]. That recommendation is graded at the Evidence Level B (some risk of bias) level, reflecting consistent trial data across multiple RCTs [5].

The Cochrane review of penile rehabilitation after radical prostatectomy (Moncada et al.) notes that alprostadil injection is the most studied pharmacological option for post-prostatectomy ED and that early penile rehabilitation with PGE1 may preserve erectile tissue oxygenation, though long-term functional benefit remains under investigation [17]. For New Jersey patients recovering from robot-assisted prostatectomy at centers such as RWJBarnabas or Hackensack Meridian, access to compounded or discounted alprostadil during the rehabilitation window (typically six to eighteen months post-surgery) is a concrete clinical priority.